CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Dec. 28, 2013	Dec. 29, 2012
Cash Flows from Operating Activities:
Net income	$ 24,964	$ 26,239
Non-cash items:
Depreciation and amortization	59,063	46,741
Amortization of financing costs	1,170	452
Stock compensation expense	9,664	7,931
Purchase of in-process R&D	3,569	0
Asset write downs and loss on sale of property, plant and equipment	2,212	472
Unrealized loss from hedging activities	351	617
Contingent consideration expense	1,182	0
Change in operating assets and liabilities:
Decrease/(increase) in accounts receivable, net	20,432	(32,165)
Increase in inventories	(24,627)	(12,732)
Increase in prepaid income taxes	(2,124)	(1,673)
Decrease/(increase) in other assets and other liabilities	5,219	(4,489)
Tax benefit of exercise of stock options	2,906	3,905
(Decrease)/Increase in accounts payable and accrued expenses	(15,928)	22,234
Net cash provided by operating activities	88,053	57,532
Cash Flows from Investing Activities:
Capital expenditures on property, plant and equipment	(43,721)	(49,685)
Proceeds from sale of property, plant and equipment	197	1,290
Acquisition of Hemerus	0	(535,144)
Acquisition of Hemerus	(23,124)	(1,000)
Other acquisitions and investments	(8,374)	0
Net cash used in investing activities	(75,022)	(584,539)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(715)	(658)
Net (decrease)/increase in short-term loans	(4,426)	4,557
Term loan borrowing	0	475,000
Repayment of term loan borrowings	(28,531)	0
Debt issuance costs	0	(5,461)
Proceeds from employee stock purchase plan	5,229	4,142
Proceeds from exercise of stock options	11,699	28,342
Excess tax benefit on exercise of stock options	2,076	3,158
Share repurchase	0	(18,042)
Net cash (used in)/provided by financing activities	(14,668)	491,038
Effect of exchange rates on cash and cash equivalents	363	289
Net Decrease in Cash and Cash Equivalents	(1,274)	(35,680)
Cash and Cash Equivalents at Beginning of Period	179,120	228,861
Cash and Cash Equivalents at End of Period	177,846	193,181
Non-cash Investing and Financing Activities:
Transfers from inventory to fixed assets for placements of Haemonetics equipment	7,967	19,606
Supplemental Disclosures of Cash Flow Information:
Interest paid	6,973	4,020
Income taxes paid	$ 4,093	$ 8,900